Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.38 |
| ▸ | CDC42 | P60953 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28610110 | 1.00 | ROCK2 (0.40) | ROCK2POLBMEN1KMT2AGRM5 | |
| SCHEMBL30087939 | 0.80 | XDH (0.44) | ROCK2GRM5IKBKBCHUK | |
| SCHEMBL28604961 | 0.80 | XDH (0.44) | ROCK2GRM5IKBKBCHUK | |
| SCHEMBL21920694 | 0.78 | NR3C1 (0.49) | GRM5TRPV1 | |
| SCHEMBL30087920 | 0.78 | NR3C1 (0.49) | GRM5TRPV1 | |
| SCHEMBL30087915 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL28919719 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10634763 | 0.69 | POLB (0.73) | POLBMEN1KMT2AGAA | |
| SCHEMBL31384762 | 0.67 | HPGD (0.60) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL988532 | 0.67 | KEAP1 (0.56) | GRM5IKBKBCHUKALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | ROCK2 2224/4885POLB 3416/4885MEN1 1717/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | ROCK2 2224/4885POLB 3416/4885MEN1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.